Products / Services

At present, the company has established extensive, in-depth and long-term cooperative relationships with many hospitals, and researches on multiple cancers such as lung cancer, colorectal cancer and gynecological tumors. The research direction covers the screening of early tumor markers and the prognosis. evaluation, tumor heterogeneity molecular classification and other fields, and

achieved fruitful results.

Genecast PD-L1

Genecast PD-L1, our therapy selection and IHC-based assay LDT service, which uses either Ventana PD-L1 (SP142) or Dako PD-L1 (22C3) monoclonal antibody kit to provide protein detection reports for PD-L1, PD-1 and four types of deficiencies in mismatch repair (“MMR”) in multiple types of solid tumors. 


It uses normal human tonsil tissue as positive and negative controls and has high sensitivity and good repeatability for detecting PD-L1, PD-1 and four types of deficiencies in MMR proteins. 


We provide Genecast PD-L1 as our LDT services under our central laboratory business model. 


Genecast PD-L1 can be tested in combination with Genecast Comprehensive.